Haleon cancels 1.4M shares in second tranche buyback at 354.8p

Q: What exactly did Haleon (HLN) buy back?

Haleon purchased and cancelled 1,400,000 ordinary shares of \u00A3.01 each.

Q: When and where were the shares purchased?

The purchases occurred on 12 August 2025 on the London Stock Exchange .

Q: What prices did Haleon pay for the shares?

Highest price paid was 356.1000p , lowest was 353.2000p , and the VWAP was 354.8037p .

Q: How many shares does Haleon have after the transaction?

Registered share capital is 8,977,135,788 ordinary shares; 3,880,205 are treasury shares; shares with voting rights total 8,973,255,583 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 1,400,000 ordinary shares of \u00A3.01 each under the second tranche of its buyback programme. The purchases occurred on 12 August 2025 on the London Stock Exchange with a highest price of 356.1000p, lowest of 353.2000p and a volume weighted average price of 354.8037p.

After settlement the company reports registered share capital of 8,977,135,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,973,255,583 ordinary shares with voting rights. The announcement includes a breakdown of individual trades under the Market Abuse Regulation and provides links for shareholders to verify holdings for FCA notification thresholds.

Positive

Executed buyback: Company purchased and cancelled 1,400,000 ordinary shares under the second tranche of its buyback programme.
Transparent disclosure: Provided trade-level prices and VWAP (354.8037p) and updated registered capital and voting share counts for FCA notification purposes.

Negative

None.

Insights

TL;DR: Haleon executed a small tranche-two buyback of 1.4M shares at a VWAP of 354.8037p; impact on capital structure is minimal.

The company purchased and cancelled 1,400,000 ordinary shares on 12 August 2025 at a VWAP of 354.8037p. Relative to the reported registered share capital of 8,977,135,788 shares, this tranche represents approximately 0.016% of the register, indicating the transaction is operationally routine and unlikely to materially affect per-share metrics or capital ratios on its own. The filing supplies full trade breakdowns per MAR, supporting regulatory transparency.

TL;DR: The buyback was disclosed with required regulatory detail and updated share counts; procedural compliance appears documented.

Haleon disclosed that the 1.4M shares were purchased for cancellation under an announced programme and provided updated figures for registered capital, treasury shares and voting shares. The announcement references a full individual trade breakdown under MAR and points shareholders to the company website, which aligns with disclosure requirements for share purchases and shareholder notification rules under the FCA. No governance issues or deviations from routine disclosure are evident in the text provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/13/2025 - 06:22 AM

FAQ

What exactly did Haleon (HLN) buy back?

Haleon purchased and cancelled 1,400,000 ordinary shares of \\u00A3.01 each.

When and where were the shares purchased?

The purchases occurred on 12 August 2025 on the London Stock Exchange.

What prices did Haleon pay for the shares?

Highest price paid was 356.1000p, lowest was 353.2000p, and the VWAP was 354.8037p.

How many shares does Haleon have after the transaction?

Registered share capital is 8,977,135,788 ordinary shares; 3,880,205 are treasury shares; shares with voting rights total 8,973,255,583.

Where can I find the full breakdown of individual trades?

A full breakdown is available via the link quoted in the announcement and on Haleon"http://www.rns-pdf.londonstockexchange.com/rns/0708V_1-2025-8-12.pdf" and on the company website at www.haleon.com/investors.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒

Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	13 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

13 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,400,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	12 August 2025	12 August 2025	12 August 2025
Number of Shares purchased:	1,400,000	-	-
Highest price paid per Share (p):	356.1000	-	-
Lowest price paid per Share (p):	353.2000	-	-
Volume weighted average price paid per Share (p):	354.8037	-	-

Following the settlement of the above, the Company's registered share capital is 8,977,135,788 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,973,255,583 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/0708V_1-2025-8-12.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 13, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

Source: View Original Filing on SEC EDGAR